
FDA Grants Priority Review to Zepzelca Combo for Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has accepted the supplemental new drug application of Zepzelca (lurbinectedin) plus Tecentriq (atezolizumab) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer whose …